Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci
about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusEfficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditisIn vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic modelIn vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate.Heterologous expression in Escherichia coli of the first module of the nonribosomal peptide synthetase for chloroeremomycin, a vancomycin-type glycopeptide antibiotic.In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptideTotal syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptideRedesign of glycopeptide antibiotics: back to the futureStructures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonanceCharacterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin.Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.Identification and analysis of the balhimycin biosynthetic gene cluster and its use for manipulating glycopeptide biosynthesis in Amycolatopsis mediterranei DSM5908Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies.Intravenous mouse infection model for studying the pathology of Enterococcus faecalis infections.Semiquantitation of cooperativity in binding of vancomycin-group antibiotics to vancomycin-susceptible and -resistant organisms.Vancomycin leading to lupus flare in an elderly lady: a case report.Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis.The Carboxyl Terminus of Eremomycin Facilitates Binding to the Non-d-Ala-d-Ala Segment of the Peptidoglycan Pentapeptide Stem.
P2860
Q24556635-1EF9DABB-1100-4B8C-A405-5C4EF6359EC4Q33693084-F0BE62DA-1ADC-4BB3-8539-8A0F59EF4631Q33697465-7F3E255F-05C9-4948-8FBA-B4E148761573Q33698979-FB83EA04-B411-44B8-83B3-F0807CD34E83Q33700343-09AA2E0B-517B-498D-9027-D3747A400915Q33976444-DACC63AC-1C61-44D3-8C99-1C5C6A81E62FQ33979559-EC5E773B-B2F2-4414-90F1-7887050F61A1Q34282738-A4608AED-2975-4762-A98F-9450BBA8A922Q35021822-8036C1C7-6557-44A5-A1C4-8BDE73392D30Q35106259-A8C86653-8D4A-449C-80BB-3060BD7D5CD0Q35138478-F15A7C92-445F-415B-B82A-B68553AD0A1FQ35224649-DB51626B-CF95-46D8-A8C1-5F7A99BFFE8EQ35973511-5CF56294-3BBF-44F9-9661-5A57B143656EQ36824435-87FC82A8-F159-44D3-994D-F3862596BE5AQ37357546-9C9D1D7D-7EA2-4D43-8726-A9EDDE405E69Q39258608-453082EC-6127-4626-91F6-7E0D642B155BQ39471118-E104950F-E35A-471C-B6DA-A305A02ECFF9Q39652572-B6CCACB1-FDCF-4CD5-A336-D919D0762383Q39730141-2E028E59-0CEC-40B3-968B-479F9DCEF6D0Q39785260-8949407F-2C9F-4729-B042-B975A3DAC775Q40376977-F7A421DC-23F2-40D9-A673-825E6E7067ACQ41290708-625E7886-A8FD-4689-BC21-6778546FAA05Q41493636-32CDEF17-C646-42E3-9A60-5AB7594209A6Q48336817-3AA96DB1-5E25-4068-8B64-90896953C906Q51571264-411D95CE-7219-49A1-A6BB-BB5E092D405C
P2860
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@ast
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@en
type
label
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@ast
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@en
prefLabel
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@ast
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@en
P2093
P2860
P356
P1476
Semisynthetic glycopeptide ant ...... ncomycin-resistant enterococci
@en
P2093
Flokowitsch JE
Preston DA
Rodriguez MJ
Thompson RC
Zweifel MJ
P2860
P304
P356
10.1128/AAC.40.9.2194
P407
P577
1996-09-01T00:00:00Z